论文部分内容阅读
新生儿同种免疫性血小板减少症(NAIT)是由于母体免疫性对抗胎儿血小板而使大约1/3000的活婴受到损害。在人血小板抗原-1a(PHA-1a)的NAIT中,母亲是PHA-1b(P1~(A2))抗原的纯合子,胎儿是PHA-1a/PHA-1b杂合子。NAIT能引起胎儿中枢神经系统严重出血和高达10％患者死亡或各种神经后遗症(高达病例的20％)。子1代有50％病例受到损害,复发的发病率为90％。子2代PHA-1a/PHA-1b杂合子的同胞比先证者通常更严重地受到损害。因此将来妊娠处理必须以预防严重并发症为目的,特别是预防妊娠期间胎儿颅内出血(ICH)和产伤。在超声波引导下通过经皮穿刺脐带
Neonatal alloimmune thrombocytopenia (NAIT) compromises approximately one third of live births due to maternal immunity against fetal platelets. In NAIT of human platelet antigen-1a (PHA-1a), the mother is a homozygote of PHA-1b (P1- (A2)) antigen and the fetus is a PHA-1a / PHA-1b heterozygote. NAIT can cause severe hemorrhage in the CNS and up to 10% of fetal deaths or various neurological sequelae (up to 20% of cases). Fifty percent of the children in the first generation are damaged, and the incidence of recurrence is 90%. The second generation of PHA-1a / PHA-1b heterozygote siblings are usually more severely damaged than probands. Therefore, future pregnancy treatment must be aimed at the prevention of serious complications, especially in the prevention of fetal intracranial hemorrhage during pregnancy (ICH) and birth trauma. Percutaneous umbilical cord under ultrasound guidance